ARFORMOTEROL TARTRATE

Post-LOE

arformoterol tartrate inhalation

ANDAINHALATIONSOLUTION

Approved

Jun 2021

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

ARFORMOTEROL TARTRATE (arformoterol tartrate inhalation) is arformoterol, the (r,r)-enantiomer of formoterol, is a selective long-acting beta 2 -adrenergic receptor agonist (beta 2 -agonist) that has two-fold greater potency than racemic formoterol (which contains both the (s,s) and (r,r)-enantiomers). Approved for acute deteriorations of chronic obstructive pulmonary disease, asthma, acute deteriorations of chronic obstructive pulmonary disease [ see ] and 2 more indications. First approved in 2021.

Drug data last refreshed 4h ago

Mechanism of Action

Arformoterol, the (R,R)-enantiomer of formoterol, is a selective long-acting beta 2 -adrenergic receptor agonist (beta 2 -agonist) that has two-fold greater potency than racemic formoterol (which contains both the (S,S) and (R,R)-enantiomers). The (S,S)-enantiomer is about 1,000-fold less potent as…

Indications (5)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.